Patent · US Active

Anti-IGF antibodies

US8318159B2 · kind B2 · utility

10Cited by

11References

13Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Paul Adam · Wien, AT
Eric Borges · Weitensfeld im Gurktal, AT

Key dates

Filing date	Dec 11, 2009
Grant date	Nov 27, 2012
Priority date	—
Expiry date	Feb 17, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.